Email Updates

You are here

Home»Media

AVAC in the News

  • 2nd Drug for HIV Prevention OK'd FDA approves F/TAF (Descovy) as PrEP regimen

    As expected, the FDA granted a pre-exposure prophylaxis (PrEP) indication to the HIV drug combination emtricitabine/tenofovir alafenamide (F/TAF, Descovy), to prevent infection in at-risk individuals except those who have receptive vaginal sex.

    October 3, 2019
    PrEP
    MedPage Today

  • Queer Eye Star Jonathan Van Ness Recalls the Moment He Discovered He Was HIV-Positive After Fainting in the Middle of Styling a Client’s Hair: ‘It Was the Moment You Dread Hearing’

    Jonathan Van Ness is coming forward about the moment he discovered he was HIV-positive. The Queer Eye star talked about the news in an interview with NBC's TODAY on Tuesday and also chatted about its connection to his new memoir, Over The Top.

    September 24, 2019
    General
    Daily Mail

  • Communities Should Be Involved in Research. Here Are Some Key Insights on Good Participatory Practice

    Communities need to be involved in research — not just as participants, but also in shaping the research project, say AVAC and UNAIDS' Good Participatory Practices guidelines (GPP). But how are these guidelines implemented, and what is the outcome? Researchers shared their experiences at the International AIDS Society Conference in July.

    August 28, 2019
    General
    The Body Pro

  • Potential New PrEP Drug Exposes Gaps in Data for Women

    Among all the CAR-T commotion you may have missed it: An FDA panel on Wednesday recommended Gilead’s Descovy to block HIV transmission in men and transgender women, a step toward another PrEP finally coming to market (the sole medicine right now being Gilead’s Truvada). One potential snag — the advisory committee narrowly voted not to recommend the medicine, which is already approved to treat HIV, for women who are not transgender, also referred to as cisgender women.

    August 9, 2019
    PrEP
    Politico

  • FDA Panel: Split Decision for Descovy in PrEP

    An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis (PrEP) to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. But murmurs echoed throughout the room as the FDA's Antimicrobial Drugs Advisory Committee split 8-10 on whether to recommend a PrEP indication for F/TAF in cisgender women.

    August 7, 2019
    PrEP
    MedPage Today

  • What Does the HOPE Study Say About the Future of the Vaginal Ring for HIV Prevention?

    A flexible vaginal ring loaded with the HIV antiretroviral dapivirine has been hailed as an exciting new HIV prevention option, particularly for women in sub-Saharan Africa who say the insertable vaginal ring is easier to use and more discreet than existing HIV prevention methods.

    August 6, 2019
    Microbicides
    The BodyPro

  • Controversy Erupts Around Study on Contraception and HIV Risk

    A landmark study evaluating HIV risk and hormonal contraception is under fire, with critics arguing the trial was ethically flawed from the start and that its results may limit already narrow birth-control options for African women.

    August 5, 2019
    Hormonal Contraceptives and HIV
    The BodyPro

  • Experts Call for Increased Local HIV Funding

    Funding for HIV prevention research and development is slowing down, according to a new report by the Resource Tracking for HIV Prevention Research and Development Working Group, a collaboration between global HIV organisations – AVAC, IAVI and UNAIDS.

    July 31, 2019
    General
    Independent

  • Is End to HIV Epidemic in Reach?

    The tools needed to end the worldwide AIDS epidemic are either in the hands of clinicians, governments, or patients, or can be implemented by using government and social willpower, researchers said here at the International AIDS Society Conference on HIV Science.

    July 26, 2019
    General
    MedPage Today

  • Writing's On The Wall: No #endAIDS Without #endTB

    TB and HIV both are preventable, but cutting the chain of transmission of HIV and TB is proving to be a daunting task. Treatment exists for both TB and HIV but disease-burden and deaths every year are indeed alarming. With countdown on towards TB and AIDS elimination targets for 2030, the writing on the wall is clear: business as usual and 'more of the same' approach is more likely to fail us.

    July 26, 2019
    Modern Ghana

Pages